Progyny, INC 8-K filings

Progyny, Inc. announced amendments to its Certificate of Incorporation and Bylaws, effective May 21, 2026, eliminating certain supermajority voting requirements.

Progyny's Board of Directors has authorized a new share repurchase program allowing for the buyback of up to $200 million of its common stock.

Progyny announced record first quarter 2026 revenue of $328.5 million, driven by robust demand for its women's health and family building solutions and a 12.2% increase excluding a former large client.

Progyny, Inc. announces settlement of a derivative action, implementing new corporate governance reforms to cap non-employee director compensation.

Progyny, a leader in women's health and family building solutions, announced record full-year 2025 financial results and provided optimistic guidance for 2026.

Progyny, Inc. announced updated financial expectations for Q4 and full year 2025, anticipating results slightly above previous guidance.

Progyny, Inc. announced the departure of President Michael Sturmer, effective December 31, 2025, with no successor named due to enhanced executive leadership.

Progyny, Inc. announced robust third-quarter 2025 financial results, including 9.3% revenue growth and a raised full-year outlook, driven by strong member engagement and successful client acquisition.

Progyny, Inc. announced record second quarter 2025 revenue of $332.9 million, a 9.5% increase, and raised its full-year financial guidance due to increased member engagement.

Progyny, Inc. has announced the establishment of a new $200 million revolving credit facility to enhance financial flexibility and expects its second quarter 2025 financial results to slightly exceed previous guidance.

Progyny, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where shareholders elected directors and ratified auditors, but notably did not approve the compensation of named executive officers on an advisory basis.

Progyny announces strong Q1 2025 results with record revenue of $324.0 million, a 16.5% increase year-over-year, and raises its full-year guidance.

Dr. Fred E. Cohen will not seek reelection to Progyny's Board of Directors at the 2025 Annual Meeting of Stockholders.

Progyny, Inc. announced its Q4 2024 financial results, reporting a 10.6% increase in quarterly revenue to $298.4 million and issuing financial guidance for 2025, projecting continued revenue growth.

Progyny announces a strong finish to 2024 with a 10.6% increase in quarterly revenue, reaching $298.4 million, and issues financial guidance for 2025 projecting continued revenue growth.

Progyny, Inc. has appointed Debra Morris to its Board of Directors and Compensation Committee, effective January 16, 2025.

Progyny anticipates fourth quarter and full year results to be slightly above previously provided financial guidance, driven by favorable member activity.

Progyny reported its third quarter 2024 financial results, highlighting a strong sales season with over 80 new clients and 1.1 million new covered lives, but also noted lower-than-expected revenue and profitability due to changes in member treatment patterns.

Progyny, Inc. has been notified of a significant client's termination of services effective January 1, 2025, which represents 12-13% of their revenue, but the company anticipates continued growth in 2025.

Progyny, a fertility benefits company, presented its long-term growth strategy at its inaugural Investor Day, targeting significant revenue and profitability increases by 2028.

Progyny announced strong second-quarter results with record adjusted EBITDA and a new $100 million share repurchase program, despite a slight revision in revenue expectations for the second half of the year.

Progyny, Inc. held its 2024 Annual Meeting of Stockholders on May 23, 2024, where stockholders voted on the election of directors, ratification of the independent auditor, and executive compensation.

Progyny's Board of Directors has authorized a new share repurchase program of up to $100 million, funded by existing cash reserves.

Progyny's first quarter results showed revenue growth but were impacted by lower-than-expected utilization in March, leading to a revised full-year outlook.

Progyny announced record full-year revenue of $1.0886 billion, a 38% increase year-over-year, and provided financial guidance for 2024, projecting revenue to exceed $1.3 billion at the midpoint.